From my understanding of the agreement—and again, that's an agreement between the National Research Council and CanSino—the National Research Council is being provided with the seed stock of the vaccine and will be able to manufacture it in Canadian facilities, not for sale but for utilization in Canada, once the Canadian manufacturing capability is up and running. It's by that method that Canada's supply will be assured because we'll have the manufacturing capacity here in Canada.
On July 6th, 2020. See this statement in context.